SN50 |
Catalog No.GC31642
One-Click Copy Product Info
|
SN50, the NF-κB cell permeable inhibitory peptide.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 213546-53-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SN50, the NF-κB cell-permeable inhibitory peptide. It is comprised of the hydrophilic region of the signal peptide of Kaposi fibroblast growth factor as a membrane translocating motif and a nuclear localization sequence derived from the p50 subunit of NF-κB[1].
SN50(20 µg/ml; 12 hs) could induce the microglia differentiation into M2 type through the NF-κB pathway. The SN50-induced microglia can protect neurons from hypoxic injury[2]. SN50 (25 µg/ml; 24 hs) could induce robust differentiation of GSCs, and the differentiated daughter cells lose the neuroglobular motility, invasiveness, and treatment insensitivity tumorigenicity of tumor stem cells[4].
SN50(100µl,10,30,60µg/ml; i.p.;1h) attenuated alveolar hypercoagulation and fibrinolysis inhibition in ARDS via inhibition of NF-κB p65 translocation[5].SN50(1µM) protected against LPS-induced lung injury in isolated rat lungs by inhibiting NF-κB nuclear translocation[6]. Topical SN50 (10µM; 12 days) suppressed nuclear factor-κB activation in local cells and reduced the incidence of epithelial defects/ulceration in C57BL/6 mice healing corneas[7].
References:
[1]. Lin YZ, Yao SY,et al. Inhibition of nuclear translocation of transcription factor NF kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270(24):14255-8.
[2]. Chian CF, Chiang CH, et, al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[3]. Zhang L, Ren X, et, al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol Ther. 2014 May;15(5):602-11. doi: 10.4161/cbt.28158. Epub 2014 Feb 20. PMID: 24557012; PMCID: PMC4026083.
[4]. Zhao K, Zhu BS, et, al. SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901. Arch Med Sci. 2013 Dec 30;9(6):990-8. doi: 10.5114/aoms.2013.39790. Epub 2013 Dec 26. PMID: 24482641; PMCID: PMC3902720.
[5]. Wu Y, Wang Y, et, al.SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation. Respir Res. 2020 May 27;21(1):130. doi: 10.1186/s12931-020-01372-6. PMID: 32460750; PMCID: PMC7251840.
[6]. Chian CF, Chiang CH, et, al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[7]. Saika S, Miyamoto T, et,al. The therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in the treatment of corneal alkali burns in mice. Am J Pathol. 2005 May;166(5):1393-403. doi: 10.1016/s0002-9440(10)62357-7. PMID: 15855640; PMCID: PMC1606394.
| Cell experiment [1]: | |
|
Cell lines |
Glioma stem-like cells GSC11 and GSC23 cells |
|
Preparation Method |
Cells were cultured in medium containing 2% B-27, 20 ng/mL EGF, and 20 ng/mL β-FGF in the presence or absence of SN50 (25 µg/mL) for twenty-four hours. |
|
Reaction Conditions |
25 µg/ml; 24 hours |
|
Applications |
SN50 can induce GSC differentiation. |
| Animal experiment [2]: | |
|
Animal models |
Male Balb/c mice(8-12 weeks) |
|
Preparation Method |
Mice was made by 50 µl of lipopolysaccharide (LPS) (4 mg/ml) inhalation. Mice were intraperitoneally injected with different does of SN50 1 h before LPS inhalation. |
|
Dosage form |
100µl,10,30,60µg/ml; i.p.;1h |
|
Applications |
SN50 inhibited expressions of TF and PAI-1 in mRNA and in protein levels in LPS-induced acute respiratory distress syndrome (ARDS) mice. |
|
References: [1]. Zhang L, Ren X, et,al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol Ther. 2014 May;15(5):602-11. doi: 10.4161/cbt.28158. Epub 2014 Feb 20. PMID: 24557012; PMCID: PMC4026083. | |
| Cas No. | 213546-53-3 | SDF | |
| Canonical SMILES | Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro | ||
| Formula | C129H230N36O29S | M.Wt | 2781.5 |
| Solubility | Water : ≥ 50 mg/mL (17.98 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 359.5 μL | 1.7976 mL | 3.5952 mL |
| 5 mM | 71.9 μL | 359.5 μL | 719 μL |
| 10 mM | 36 μL | 179.8 μL | 359.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)